PODD

Insulet Corp.

Fundamental data last updated:November 20, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

02/17/2027

Business Summary

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

 


VALUATION

P/E

24.79

Market Cap ($M USD)

$10.58B

Forward P/E

22.39

PEG

0.63

PRICE TO SALES

3.32

PRICE TO BOOK

6.70

EV / EBITDA

15.96

5-Year Average P/E

Free Cash Flow Yield

2.46%

DCF Value

$-38.03

Graham Number

$56.28

Price to FCF

40.68

EV to FCF

42.14

Earnings Yield

4.05%

FCF Yield

2.46%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$6.18

Next Year EPS Growth Estimate

$6.81

Next Year Revenue Growth Estimate

$3.31B

Return on Equity (ROE)

29.48%

FREE CASH FLOW

Operating Margin

18.43%

Debt-to-Equity

0.61

Piotroski F-Score

7

Altman Z-Score

5.66

Return on Invested Capital (ROIC)

17.53%

Current Ratio

2.51

Quick Ratio

1.83

Net Debt to EBITDA

0.55

Interest Coverage

9.81

Gross Profit margin

71.88%

FCF PER SHARE

$3.75

REVENUE PER SHARE

$45.98

Gainseekers Quantitative Analysis

Summary

PODD Insulet Corporation’s valuation presents a mixed picture. Despite a robust Forward P/E of 10.64, suggesting potential undervaluation, the market price has traded significantly below its DCF Value, indicating skepticism about future cash flows. The Altman Z-score of 5.87 underscores financial stability, while an Earnings Yield of just 2.81% raises questions about immediate returns. With a Graham Number far below the current price, the stock appears overvalued on a fundamental basis, yet its growth prospects remain compelling.

AI Exposure / Tech Reliance

Operating within the Medical Devices industry, Insulet is well-positioned to leverage AI advancements in healthcare. The sector's increasing reliance on data-driven solutions aligns with Insulet's innovative approach to diabetes management. This adaptability could enhance operational efficiencies and patient outcomes.

The Bull Case

For the discerning GARP investor, Insulet offers a compelling narrative. A stellar ROIC of 22.06% highlights exceptional capital efficiency, while a Piotroski F-Score of 7 indicates strong financial health. The company's operating margin of 17.48% and a solid FCF Yield suggest robust pricing power and cash generation capabilities. These metrics paint a picture of a company with the potential for sustainable growth and profitability.

The Bear Case

However, the stock is not without its pitfalls. A Price/Book ratio of 8.28 and Price/Sales of 3.68 suggest a premium valuation, potentially limiting upside. The technical overextension, with a distance to the 52-week high at 130.20%, signals caution. Additionally, the EV to FCF ratio of 27.04 implies that the market may be overestimating future cash flow potential, presenting a risk for value investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$178.41

Institutional Ownership %

1-Year Beta

1.06

Insider Buying % (6 Mo)

Distance to 52-Week High

132.74%

Distance to 52-Week Low

17.10%

EARNINGS SURPRISE %

25.16%

50-DAY SMA

$142.14

200-DAY SMA

$172.70

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.